Company Summary

IDI is a start-up specialty biopharmaceutical company. The lead indication for IDI is basal cell carcinoma (BCC), the most common skin cancer and also the most common among all cancers. The drug development program involves repurposing of an oral inhibitor of the Hedgehog biologic pathway, a key pathway exhibiting abnormal regulation in various cancers, for local administration.

Team

Arthur Peter Bertolino

CEO

Dr. Bertolino is a Board Certified dermatologist with over 13 years of biotech/pharma drug development experience. Prior to founding IDI, he led clinical programs at Novartis, Pfizer and Peplin. He contributed to development and approval of Ilaris® and Picato®, as well other innovative drugs. He received his clinical and scientific training at Johns Hopkins and NYU and business training at the Ross School of Business (Univ. of Michigan).